• Nie Znaleziono Wyników

Intraventricular thrombus progression due to poor compliance with anticoagulant treatment in a patient with hypereosinophilic and antiphospholipid syndromes

N/A
N/A
Protected

Academic year: 2022

Share "Intraventricular thrombus progression due to poor compliance with anticoagulant treatment in a patient with hypereosinophilic and antiphospholipid syndromes"

Copied!
2
0
0

Pełen tekst

(1)

KARDIOLOGIA POLSKA 2019; 77 (4) 480

syndrome and antiphospholipid syndrome in‑

volving the heart and leading to endocardial fi‑

brosis and apical thrombus formation in the left ventricle (LV), as shown on cardiac magnetic resonance (FIGURE 1). Because of a mental disor‑

der, the patient presented poor compliance with anticoagulant (low‑molecular‑weight heparin [LMWH]) and immunosuppressive treatment since the last hospitalization.

Transthoracic echocardiography on admis‑

sion showed an extremely large thrombus al‑

most occluding the LV from the mid to apical seg‑

ments, with an impairment of LV contractility.

A comparative cardiac magnetic resonance con‑

firmed thrombus enlargement from 22 × 31 mm to 29 × 44 mm and revealed a more advanced Hypereosinophilic syndrome is an uncommon

disorder defined as persistent eosinophilia (ab‑

solute eosinophil count >1500/μl) associated with single or multiple organ dysfunction, where other causes of hypereosinophilia have been ex‑

cluded. Cardiac involvement occurs in more than 50% of cases and is a major cause of morbidity and mortality in this patient group.1‑3 The out‑

come depends on the development of endocar‑

dial fibrosis and related complications; there‑

fore, early diagnosis and proper medical treat‑

ment are crucial to prevent disease progression.

A 63‑year‑old man was referred to our de‑

partment due to exacerbation of heart failure symptoms and atypical chest pain. Six months earlier he was diagnosed with hypereosinophilic

Correspondence to:

Marcin Książczyk, MD, Department  of Interventional Cardiology  and Cardiac Arrhythmias,  Medical University of Lodz,  ul. Żeromskiego 113, 90‑549 Łódź,  Poland, phone: +48 42 639 35 63,  email: marcin_ksiazczyk@interia.pl Received: January 10, 2019.

Revision accepted:

January 30, 2019.

Published online: April 25, 2019.

Kardiol Pol. 2019; 77 (4): 480‑481 doi:10.33963/KP.14802 Copyright by Polskie Towarzystwo  Kardiologiczne, Warszawa 2019

C L I N I C A L V I G N E T T E

Intraventricular thrombus progression due to poor compliance with anticoagulant treatment in a patient with hypereosinophilic and

antiphospholipid syndromes

Karolina Szymańska, Marcin Książczyk, Agnieszka Dębska‑Kozłowska, Tomasz Grycewicz, Andrzej Lubiński Department of Interventional Cardiology and Cardiac Arrhythmias, Medical University of Lodz, Łódź, Poland

A B C

FIGURE 1  An initial cardiac magnetic resonance: an apical left ventricular thrombus (arrow) and areas of endocardial fibrosis; A – cinematographic sequence; B – late gadolinium enhancement sequence; C – early gadolinium enhancement sequence in the 4‑chamber view

(2)

C L I N I C A L V I G N E T T E Intraventricular thrombus progression in a patient with HES and APS 481 endocardial fibrosis (FIGURE 2). Evidence‑based

therapy was administered with LMWH, aza‑

thioprine, and glucocorticoids, and the patient was finally discharged to a nursing home where he received optimal medical treatment to im‑

prove his compliance.

Follow‑up transthoracic echocardiography at 3 months showed a significant dicrease in the thrombus size without complete dissolution;

LMWH was switched to acenocumarol dosed according to the recommended therapeutic in‑

ternational normalized ratio range of 2 to 3.

ARTICLE INFORMATION

CONFLICT OF INTEREST None declared.

HOW TO CITE Szymańska K, Książczyk M, Dębska‑Kozłowska A, et al. Intraven‑

tricular thrombus progression due to poor compliance with anticoagulant treat‑

ment in a patient with hypereosinophilic and antiphospholipid syndromes. Kardi‑

ol Pol. 2019; 77: 480‑481. doi:10.33963/KP.14802

REFERENCES

1 Kleinfeldt T, Nienaber CA, Kische S, et al. Cardiac manifestations of the hypere‑

osinophilic syndrome: new insights. Clin Res Cardiol. 2010; 99: 419‑427.

2 Beedupalli J, Modi K. Early‑stage Loeffler’s endocarditis with isolated right  ventricular involvement: management, long‑term follow‑up, and review of liter‑

ature. Echocardiography. 2016; 33: 1422‑1427.

3 Sivasankaran  S,  Harikrishnan  S,  Tharakan  JM.  Left  ventricular  thrombi  in  the presence of normal left ventricular function. Indian Heart J. 2002; 54: 196‑198.

A B C

FIGURE 2 A comparative cardiac magnetic resonance at 6 months after a period of poor compliance to anticoagulant treatment: an extremely large thrombus (arrow) in the apical to mid segments of the left ventricle and more extended areas of advanced endocardial fibrosis; A – cinematographic sequence; B – late gadolinium enhancement sequence; C – early gadolinium enhancement sequence in the 4‑chamber view

Cytaty

Powiązane dokumenty

The aim of the present study was an assessment of alendronate compliance (administered daily) during the treatment of osteoporosis within the period of 6 and 18 months in the

Żywności i Leków (FDA, Food and Drug Ad- ministration) oraz Europejska Agencja Leków (EME, European Medicines Agency) dopuściły stosowanie BV u pacjentów z nawrotem choroby

Potent, transient in- hibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic

Nilotynib, TKI II generacji, wcześniej znany jako AMN107, został zatwierdzony przez FDA 29 paź- dziernika 2007 roku — początkowo w leczeniu dorosłych chorych na CML w

Left ventricular giant thrombus mimicking a primary cardiac tumor with recurrent systemic embolism in a patient with primary antiphospholi- pid syndrome has not been

3 On the other hand, technical faults of stent implantation: small diameter, stent underexpansion, incomplete stent struts apposition, or dissections are mostly responsi‑. ble

Transthoracic echocardiography (TTE) revealed a large, irregular, and soft pathological mass, of 48 × 32 mm in size, which appeared to be directly attached to the anterior leaflet

W diagnostyce chorych po zawale serca należy uwzględnić APS, zwłaszcza gdy obserwuje się izolowane wydłużenie aPTT bez powikłań krwotocznych, a na pewno wówczas,